Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rakovina Therapeutics Inc ( (TSE:RKV) ) has shared an update.
Rakovina Therapeutics Inc. announced that its Chief Scientific Officer, Dr. Mads Daugaard, has been invited to present at the prestigious 13th Tuscany Retreat on Cancer Research and Apoptosis. This invitation underscores Dr. Daugaard’s contributions to cancer research and highlights Rakovina’s commitment to advancing therapies targeting the DNA-damage response. The event serves as a platform for collaboration and exchange of ideas among leading international researchers, which could potentially translate into meaningful benefits for patients.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical research company that focuses on developing innovative cancer treatments. Utilizing unique technologies powered by Artificial Intelligence, specifically the proprietary Deep-Docking™ and Enki™ platforms, the company aims to target the DNA-damage response. Rakovina has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Average Trading Volume: 67,016
Technical Sentiment Signal: Sell
Current Market Cap: C$10.57M
See more data about RKV stock on TipRanks’ Stock Analysis page.